Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease
Alzheimer’s disease is an emerging global epidemic that is becoming increasingly unsustainable. Most of the clinical trials have been centered around targeting β-amyloid and have met with limited success. There is a great impetus to identify alternative drug targets. Iron appears to be the common th...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2020.00196/full |
id |
doaj-4f3a51cf866f4b319655307a1251dea4 |
---|---|
record_format |
Article |
spelling |
doaj-4f3a51cf866f4b319655307a1251dea42020-11-25T03:24:47ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652020-07-011210.3389/fnagi.2020.00196553989Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s DiseaseAzhaar AshrafPo-Wah SoAlzheimer’s disease is an emerging global epidemic that is becoming increasingly unsustainable. Most of the clinical trials have been centered around targeting β-amyloid and have met with limited success. There is a great impetus to identify alternative drug targets. Iron appears to be the common theme prevalent across neurodegenerative diseases. Iron has been shown to promote aggregation and pathogenicity of the characteristic aberrant proteins, β-amyloid, tau, α-synuclein, and TDP43, in these diseases. Further support for the involvement of iron in pathogenesis is provided by the recent discovery of a new form of cell death, ferroptosis. Arising from iron-dependent lipid peroxidation, ferroptosis is augmented in conditions of cysteine deficiency and glutathione peroxidase-4 inactivation. Here, we review clinical trials that provide the rationale for targeting ferroptosis to delay the pathogenesis of Alzheimer’s disease (AD), potentially of relevance to other neurodegenerative diseases.https://www.frontiersin.org/article/10.3389/fnagi.2020.00196/fullAlzheimer’s diseasecystine/glutamate antiporterferroptosisglutathione peroxidase-4ironlipid peroxidation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Azhaar Ashraf Po-Wah So |
spellingShingle |
Azhaar Ashraf Po-Wah So Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease Frontiers in Aging Neuroscience Alzheimer’s disease cystine/glutamate antiporter ferroptosis glutathione peroxidase-4 iron lipid peroxidation |
author_facet |
Azhaar Ashraf Po-Wah So |
author_sort |
Azhaar Ashraf |
title |
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease |
title_short |
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease |
title_full |
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease |
title_fullStr |
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease |
title_full_unstemmed |
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease |
title_sort |
spotlight on ferroptosis: iron-dependent cell death in alzheimer’s disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2020-07-01 |
description |
Alzheimer’s disease is an emerging global epidemic that is becoming increasingly unsustainable. Most of the clinical trials have been centered around targeting β-amyloid and have met with limited success. There is a great impetus to identify alternative drug targets. Iron appears to be the common theme prevalent across neurodegenerative diseases. Iron has been shown to promote aggregation and pathogenicity of the characteristic aberrant proteins, β-amyloid, tau, α-synuclein, and TDP43, in these diseases. Further support for the involvement of iron in pathogenesis is provided by the recent discovery of a new form of cell death, ferroptosis. Arising from iron-dependent lipid peroxidation, ferroptosis is augmented in conditions of cysteine deficiency and glutathione peroxidase-4 inactivation. Here, we review clinical trials that provide the rationale for targeting ferroptosis to delay the pathogenesis of Alzheimer’s disease (AD), potentially of relevance to other neurodegenerative diseases. |
topic |
Alzheimer’s disease cystine/glutamate antiporter ferroptosis glutathione peroxidase-4 iron lipid peroxidation |
url |
https://www.frontiersin.org/article/10.3389/fnagi.2020.00196/full |
work_keys_str_mv |
AT azhaarashraf spotlightonferroptosisirondependentcelldeathinalzheimersdisease AT powahso spotlightonferroptosisirondependentcelldeathinalzheimersdisease |
_version_ |
1724600016334487552 |